Attovia Therapeutics Stock Forecast
NASDAQ: ATTOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 16.37 +0.37%
ATTO analyst consensus
Consensus (5 analysts)
strong_buy
Avg. price target
$42.20+158.74%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Attovia Therapeutics (2026-10-08), 5 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $42.20, with a high estimate of $52.00 and a low estimate of $30.00. The average target implies upside of 158.7% from the current price of $16.31.
The spread between the highest and lowest targets is 73.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ATTO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 40% |
| Buy | 3 | 60% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $30.00 | +83.94% |
| Average target | $42.20 | +158.74% |
| High target | $52.00 | +218.82% |